Chunrui R. Li

1095 Jie Fang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Editorial Note: Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein.

Editorial Note: Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein.

Journal: Oncotarget

Published: July 24, 2026

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Journal: Clinical hematology international

Published: March 31, 2026

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

Journal: Research square

Published: March 27, 2026

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

Journal: American journal of hematology

Published: March 23, 2026

METTL14-mediated m6A modification of CCNE1 accelerates progression of myelodysplastic syndromes via MAPK-ERK and PI3K-AKT signaling pathways.

METTL14-mediated m6A modification of CCNE1 accelerates progression of myelodysplastic syndromes via MAPK-ERK and PI3K-AKT signaling pathways.

Journal: Cellular signalling

Published: March 17, 2026

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.

Journal: British journal of haematology

Published: February 11, 2026

Clinical impact and prognostic implications of concurrent amyloid deposition in patients with POEMS syndrome: A single-center retrospective study.

Clinical impact and prognostic implications of concurrent amyloid deposition in patients with POEMS syndrome: A single-center retrospective study.

Journal: Annals of hematology

Published: January 30, 2026

In vivo engineering of CAR-T cells: delivery strategies and clinical translation.

In vivo engineering of CAR-T cells: delivery strategies and clinical translation.

Journal: Biomarker research

Published: January 05, 2026

A simple nomogram to help guide the diagnosis of cardiac amyloidosis in patients with heart failure with preserved ejection fraction.

A simple nomogram to help guide the diagnosis of cardiac amyloidosis in patients with heart failure with preserved ejection fraction.

Journal: Quantitative imaging in medicine and surgery

Published: December 07, 2025

Avoidance of related donors in CAEBV with germline immune variants: long-termoutcome of matched unrelated donor HSCT - a case report.

Avoidance of related donors in CAEBV with germline immune variants: long-termoutcome of matched unrelated donor HSCT - a case report.

Journal: Annals of hematology

Published: October 22, 2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 08, 2025

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.

Journal: Nature medicine

Published: July 21, 2025

Showing 1-12 of 87

Last Updated: 09/26/2026